Divi's Laboratories Ltd
NSE:DIVISLAB

Watchlist Manager
Divi's Laboratories Ltd Logo
Divi's Laboratories Ltd
NSE:DIVISLAB
Watchlist
Price: 5 998.35 INR 0.36% Market Closed
Market Cap: 1.6T INR
Have any thoughts about
Divi's Laboratories Ltd?
Write Note

Divi's Laboratories Ltd
Accounts Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Divi's Laboratories Ltd
Accounts Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accounts Receivables CAGR 3Y CAGR 5Y CAGR 10Y
Divi's Laboratories Ltd
NSE:DIVISLAB
Accounts Receivables
â‚ą21.6B
CAGR 3-Years
9%
CAGR 5-Years
323%
CAGR 10-Years
N/A
Suven Life Sciences Ltd
NSE:SUVEN
Accounts Receivables
â‚ą38.9m
CAGR 3-Years
32%
CAGR 5-Years
-53%
CAGR 10-Years
N/A
Dishman Carbogen Amcis Ltd
NSE:DCAL
Accounts Receivables
â‚ą4.6B
CAGR 3-Years
7%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Syngene International Ltd
NSE:SYNGENE
Accounts Receivables
â‚ą4.8B
CAGR 3-Years
11%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Tarsons Products Ltd
NSE:TARSONS
Accounts Receivables
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
I
Innova Captab Ltd
NSE:INNOVACAP
Accounts Receivables
â‚ą2.9B
CAGR 3-Years
28%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Divi's Laboratories Ltd
Glance View

Market Cap
1.6T INR
Industry
Life Sciences Tools & Services

Divi's Laboratories Ltd. is a prominent player in the pharmaceutical industry, primarily known for its role as a leading manufacturer of active pharmaceutical ingredients (APIs) and intermediates. Founded in 1990, the company has established a robust reputation for its high-quality products and commitment to research and development. With an extensive product portfolio that serves a multitude of therapeutic areas, including pain management, oncology, and cardiovascular treatments, Divi's has positioned itself as a trusted partner to both domestic and global pharmaceutical companies. The company's state-of-the-art manufacturing facilities, compliant with international regulatory standards, ensure that it meets the growing demand for cost-effective and high-quality APIs, which is increasingly vital as the world turns to generics and specialty medicines. For investors, Divi's Laboratories presents a compelling opportunity anchored in its sustainable growth trajectory and financial resilience. Over the years, the company has demonstrated strong revenue growth and healthy profit margins, reflecting its operational efficiency and strategic focus on innovation. With a diversified customer base across more than 95 countries, the company is well-positioned to capitalize on emerging market trends and the ongoing expansion in global healthcare requirements. As healthcare systems evolve and the demand for affordable pharmaceuticals surges, Divi’s commitment to excellence and innovation keeps it at the forefront of the industry, making it an attractive investment for those looking to align with a company that not only generates value but also significantly contributes to global health outcomes.

DIVISLAB Intrinsic Value
2 898.15 INR
Overvaluation 52%
Intrinsic Value
Price

See Also

What is Divi's Laboratories Ltd's Accounts Receivables?
Accounts Receivables
21.6B INR

Based on the financial report for Jun 30, 2024, Divi's Laboratories Ltd's Accounts Receivables amounts to 21.6B INR.

What is Divi's Laboratories Ltd's Accounts Receivables growth rate?
Accounts Receivables CAGR 5Y
323%

Over the last year, the Accounts Receivables growth was 20%. The average annual Accounts Receivables growth rates for Divi's Laboratories Ltd have been 9% over the past three years , 323% over the past five years .

Back to Top